<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04423627</url>
  </required_header>
  <id_info>
    <org_study_id>202004244</org_study_id>
    <nct_id>NCT04423627</nct_id>
  </id_info>
  <brief_title>Sympathetic Regulation of Large Artery Stiffness in Humans With ISH</brief_title>
  <acronym>SELECT</acronym>
  <official_title>Sympathetic Regulation of Large Artery Stiffness in Humans With Age-Related Isolated Systolic Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stiffening of your blood vessels, particularly the large vessels from your heart (called the
      aorta and carotids) you age contributes to the development of cardiovascular disease (CVD)
      such as heart attack and stroke. Nerve activity from your brain to your body also increases
      with advancing age but it is unknown if this nerve activity contributes directly to the
      stiffening on your blood vessels in older adults in addition to high blood pressure.
      Therefore, successful completion of the proposed aims will have a significant clinical impact
      by identifying if nerve activity from your brain could be a novel target for therapies that
      would lower stiffness of the aorta and carotid arteries in older adults.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo controlled, parallel design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in carotid-femoral pulse wave velocity</measure>
    <time_frame>Baseline and after 4 weeks</time_frame>
    <description>Aortic stiffness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in carotid distensibility index</measure>
    <time_frame>Baseline and after 4 weeks</time_frame>
    <description>Change in carotid distensibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in carotid flow pulsatility index</measure>
    <time_frame>Baseline and after 4 weeks</time_frame>
    <description>Change in carotid flow pulsatility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in carotid intimal medial thickness (IMT)</measure>
    <time_frame>Baseline and after 4 weeks</time_frame>
    <description>Change in carotid wall thickness</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Hypertension, Systolic</condition>
  <condition>Stiffness, Aortic</condition>
  <arm_group>
    <arm_group_label>Clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2 mg/day oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>37.5 mg/day oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Clonidine 0.2 mg/day oral tablet</description>
    <arm_group_label>Clonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 37.5 mg/day oral tablet</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 60-85

          -  non-smoking

          -  clinically healthy

          -  untreated or treated stage 1 isolated systolic hypertension (ISH) (systolic BP 130-139
             mmHg; diastolic BP &lt;90 mmHg) or stage 2 ISH (systolic BP 140-159 mmHg; diastolic BP
             &lt;90 mmHg) per 2017 AHA/ACC hypertension guidelines

          -  if subject is on antihypertensive medications, they will stop taking medication for a
             one-week washout period after Visit 1 before they return for Visit 2. They will come
             in at day 3 and day 7 of the one-week washout for a BP reading, to confirm that
             systolic BP is &lt;160 mmHg.

        Exclusion Criteria:

          -  no history of cardiovascular disease (e.g., myocardial infarction, bypass surgery,
             angioplasty/stent, heart failure, cardiomyopathy, pacemaker/defibrillator, peripheral
             artery disease), pulmonary disease, liver disease, Type I or II diabetes, cancer
             (treated by chemotherapy and/or radiation), psychiatric illness, on aspirin or other
             non-steroidal anti-inflammatory drugs (NSAIDs).

          -  aspirin, NSAIDs, vitamins, herbal supplements, omega-3-fatty acids will have to
             discontinue for at least 1 week before participation and remain discontinued during
             the study.

          -  blood thinners, serotonin reuptake inhibitors (SSRIs), or PDE5 inhibitors will also be
             excluded.

          -  Women must be postmenopausal for at least 6 months (surgical or natural) and not
             currently on hormone replacement therapy.

          -  Subjects not on antihypertensive will not be eligible if their resting clinic systolic
             BP is &lt;130 mmHg or &gt;160 mmHg and diastolic BP &gt;90 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Pierce, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Stroud, RN, MSN</last_name>
    <phone>3193849549</phone>
    <email>amy-stroud@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gary L Pierce, PhD</last_name>
    <phone>3193359487</phone>
    <email>gary-pierce@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Gary L. Pierce</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

